Skip to main content
Cinclus Pharma Holding AB logo

Cinclus Pharma Holding AB — Investor Relations & Filings

Ticker · CINPHA ISIN · SE0020388577 LEI · 549300TJBPSNZ3DO6B42 ST Manufacturing
Open in API
Filings indexed 68 across all filing types
Latest filing 2024-12-30 Share Issue/Capital Cha…
Country SE Sweden
Listing ST CINPHA

About Cinclus Pharma Holding AB

https://cincluspharma.com/

Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing treatments for gastric acid-related diseases. The company's lead drug candidate is linaprazan glurate, a Potassium-Competitive Acid Blocker (PCAB) in late-stage clinical development. This therapeutic is being developed to treat gastroesophageal reflux disease (GERD), particularly severe erosive GERD, and for the eradication of Helicobacter pylori infections. Linaprazan glurate represents a next-generation approach, aiming to provide superior clinical efficacy and a more beneficial pharmacokinetic profile compared to traditional Proton Pump Inhibitors (PPIs). The goal is to address the unmet medical needs of patients who do not achieve sufficient disease control with current therapies.

Recent filings

Filing Released Lang Actions
Antal aktier och röster i Cinclus Pharma
Share Issue/Capital Change Classification · 99% confidence The document explicitly details a change in the total number of shares and votes ('Antal aktier och röster') following an emission and repurchase of C-shares, effective as of December 30, 2024. This announcement concerns changes to the company's capital structure and share count, which directly relates to share issuance or capital changes. The most fitting category is 'Share Issue/Capital Change' (SHA). Although it involves a share transaction, the primary focus is the resulting total share count and capital update, making SHA more precise than POS (Transaction in Own Shares) or CAP (Capital/Financing Update), which usually covers fundraising rounds or debt issuance. The document is a formal notification of a change in the number of shares outstanding.
2024-12-30 Swedish
Number of shares and votes in Cinclus Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly details a change in the total number of shares and votes due to the 'issue and repurchase of 854,430 class C shares'. It provides the resulting total share count (47,392,219) and the change in share capital as of December 30, 2024. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it mentions a prior resolution (28 November 2024), the core content is the resulting official count update, not a general announcement of a report (RPA) or a general regulatory filing (RNS).
2024-12-30 English
Första dag för handel i Carasent AB (publ) på Nasdaq Stockholm
Delisting Announcement Classification · 100% confidence The document is a press release announcing the first day of trading for Carasent AB on Nasdaq Stockholm following a cross-border merger. It details the completion of the merger, the delisting from Oslo Børs, and the commencement of trading on the new exchange. While it mentions insider reporting, it is primarily a corporate announcement regarding listing status and market activity, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific categories like M&A (which is already completed) or Share Issue (as it is a listing event).
2024-12-09 Swedish
Linaprazan glurate får marknadsföringstillstånd i Kina
Regulatory Filings Classification · 95% confidence The document is a press release from Cinclus Pharma announcing that their drug candidate, linaprazan glurate, has received marketing authorization in China. It details the regulatory approval, the partnership with Sinorda, and the commercialization outlook. As it is a general corporate announcement regarding business operations and regulatory milestones that does not fit into specific financial reporting categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2024-12-04 Swedish
Linaprazan glurate receives marketing approval in China
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the company's drug candidate, linaprazan glurate, has received marketing approval in China. It is a short, news-style announcement (under 5,000 characters) that provides details on the regulatory milestone and includes contact information. It does not fit into specific financial reporting categories like 10-K or IR, and while it mentions an attachment, the text itself is a standard corporate regulatory announcement regarding business operations, which falls under the RNS (Regulatory Filings) category.
2024-12-04 English
Emission och återköp av C-aktier
Transaction in Own Shares Classification · 95% confidence The document text explicitly discusses the decision to conduct a new issuance ('nyemission') and subsequent repurchase ('återköp') of C-shares to secure future delivery of common shares for long-term incentive programs (PSP and ESOP). This action directly relates to changes in the company's capital structure and share issuance/repurchase activities. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA) or 'Transaction in Own Shares' (POS). Since the primary action described is the issuance and immediate repurchase of shares related to incentive plans, 'Transaction in Own Shares' (POS) is highly relevant, but 'Share Issue/Capital Change' (SHA) is a broader fit for the issuance component. Given the context of issuing shares specifically to fulfill incentive plans, which often involves a controlled transaction, POS (Transaction in Own Shares) is a strong candidate, as is SHA (Share Issue/Capital Change). However, the text details both an issuance and a repurchase, making POS (Transaction in Own Shares) slightly more specific to the described mechanism, although SHA covers the issuance aspect. Since the document is a formal announcement detailing the mechanics of issuing and immediately buying back shares, it fits best under SHA (Share Issue/Capital Change) as it fundamentally alters the share structure for incentive fulfillment, or POS (Transaction in Own Shares). Given the focus on the transaction mechanism involving the company's own shares for incentive fulfillment, POS is selected as the most precise fit for the described corporate action.
2024-11-28 Swedish

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.